Adial Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Adial Pharmaceuticals, Inc. (ADIL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $188 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2021-03-22
- Adial Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2020 was $188.00, a 98.93% decline from fiscal 2019.
- Adial Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2019 was $17.57K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2020-12-31 | $188.00 10-K · filed 2021-03-22 |
| 2019-12-31 | $17.57K 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |